Synapse - Danny Khalil

Search Within

Danny Nejad Khalil

Results (64)

Transcriptomic profiling to identify subsets of immune hot locally advanced rectal adenocarcinomas with favorable outcomes after neoadjuvant treatment

Meeting Abstract

Sanchez Vega, F.; Chatila, W. K.; Kim, J. K.; Walch, H. S.; Marco, M.; Chen, C. T.; Wu, F.; Khalil, D.; Ganesh, K.; Qu, X.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)

Meeting Abstract

Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States

Journal Article

Zou, C.; El Dika, I.; Vercauteren, K. O. A.; Capanu, M.; Chou, J.; Shia, J.; Pilet, J.; Quirk, C.; Lalazar, G.; Andrus, L.; more...
Cancer Medicine (2022)

Fulltext@MSK | Save

An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer

Meeting Abstract

Tsimberidou, A. M.; Drakaki, A.; Khalil, D.; Kummar, S.; Hodi, F. S.; Oh, D. Y.; Cabanski, C. R.; Tezlaff, M.; LaVallee, T.; Spasic, M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results

Meeting Abstract

Naing, A.; Rosen, L.; Camidge, R. D.; Khalil, D.; Davies, J.; Miles, D.; Patel, M.; Cockle, P.; Champion, B.; Krige, D.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

Journal Article

Reyngold, M.; O'Reilly, E. M.; Varghese, A. M.; Fiasconaro, M.; Zinovoy, M.; Romesser, P. B.; Wu, A.; Hajj, C.; Cuaron, J. J.; Tuli, R.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer

Journal Article

Segal, N. H.; Cercek, A.; Ku, G.; Wu, A. J.; Rimner, A.; Khalil, D. N.; Reidy-Lagunes, D.; Cuaron, J.; Yang, T. J.; Weiser, M. R.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

CDX1140-01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (part 1) and in combination with CDX-301 (part 2) or pembrolizumab (part 3)

Meeting Abstract

Sanborn, R.; Hauke, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Bordoni, R.; Gordon, M.; Khalil, D.; Abdelrahim, M.; Marron, T.; more...
Journal for ImmunoTherapy of Cancer (2020)

Fulltext@MSK | Save

Phase Ib study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma

Journal Article

Harding, J. J.; Kelley, R. K.; Tan, B.; Capanu, M.; Do, G. K.; Shia, J.; Chou, J. F.; Ferrer, C. S.; Boussayoud, C.; Muenkel, K.; more...
The Oncologist (2020)

Fulltext@MSK | Save

Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers

Meeting Abstract

Park, W.; Sokol, E.; Chen, J.; Yu, K. H.; Khalil, D.; Harding, J. J.; El Dika, I. H.; Riaz, N.; Abou-Alfa, G. K.; Kelsen, D. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save